Daiichi Sankyo Sees 7.1% Sales Rise in April-December, Cuts Domestic Forecast for Nexium

February 1, 2013
Daiichi Sankyo said on January 31 that its group sales for April-December 2012 climbed 7.1% from a year earlier to 745,632 million yen, taking heart from sales growth at its Indian subsidiary, Ranbaxy Laboratories, which markets the generic version of...read more